ArticleBMC cancer2026
The value of tertiary lymphoid structure on predicting the survival rate of advanced cervical cancer patients.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCervical cancer (CC) ranks as the fourth most prevalent cancer among women worldwide. However, for patients with advanced-stage disease, reliable prognostic markers remain scarce. In this study, we evaluated the combined prognostic value of tertiary lymphoid structures (TLS) and systemic hematological parameters in CC. MATERIALS AND
methodsIn this retrospective study, we enrolled 232 cervical cancer patients diagnosed with stage IIb-IV disease. Formalin-fixed, paraffin-embedded tissue sections were analyzed using hematoxylin-eosin (HE) staining and immunohistochemistry to quantify tertiary lymphoid structure (TLS) density. Peripheral blood samples were obtained to assess hematological parameters. The prognostic significance of these factors for overall survival (OS) was evaluated through Kaplan-Meier survival analysis and both univariate and multivariate Cox proportional hazards regression models.
resultsOur study found that high TLS expression correlated significantly with improved prognosis(HR = 0.48, 95% CI: 0.29–0.79, p = 0.004), However, LS alone demonstrated limited predictive accuracy as an independent prognostic marker (AUC = 0.559, 95% CI: 0.490–0.628). Therefore, we integrated systemic hematological parameters and identified that the combination of TLS and D-Dimer was a stronger predictor of patient survival than other factors (AUC = 0.687, 95% CI: 0.609–0.764, p < 0.001). Through multivariate Cox regression analysis, we subsequently developed a prognostic nomogram incorporating TLS, AST/ALT ratio, CEA, CA199, and D-dimer levels, providing clinicians with a novel, comprehensive tool for patient outcome assessment.
conclusionThe combination of TLS density and D-Dimer levels provides enhanced prognostic evaluation for patients with advanced cervical cancer. This approach may offer a new intervention pathway for those with poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.